Recordati SpA operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Recordati SpA with three other
pharmaceutical manufacturers in Europe:
Krka DD Novo Mesto
sales of 1.27 billion Euro [US$1.43 billion]
of which 61%
was European Union),
Vifor Pharma AG
(1.34 billion Swiss Francs [US$1.35 billion]
of which 100%
was Pharmaceutical), and
Richter Gedeon Vegyeszeti Gyar Nyilvanosan Mukodo Reszvenytarsasag
based in Hungary
(444.36 billion Hungarian Forints [US$1.55 billion]
of which 80%
was Pharmaceutical Manufacturing and Sale).
During the year ended December of 2017, sales at
Recordati SpA were 1.29 billion Euro (US$1.45 billion).
increase of 11.6%
versus 2016, when the company's sales were 1.15 billion Euro.
This was the fifth consecutive year of sales increases at Recordati SpA
(and since 2012, sales have increased a total of 56%).
Sales of Orphan Drugs saw an increase
13.1% in 2017, from
186.81 million Euro to 211.24 million Euro.